Biometric Signature ID Recommends Software Only Biometric Solution to Comply with New DEA Rule Mandating Multi-Factor Authentication for Electronic Prescribing

DALLAS, Texas (SEND2PRESS NEWSWIRE) — Biometric Signature ID (BSI) announces that it submitted formal comments to the U.S. Drug Enforcement Administration (DEA) in response to the agency’s request for comments on the Interim Final Rule enabling electronic prescribing (ePrescribing) of controlled substances. BSI introduced its BioSig-ID(TM) software biometric as a logical solution for the DEA’s identity authentication requirements.